Ambrisentan can be an endothelin receptor antagonist (Period) that was recently
Ambrisentan can be an endothelin receptor antagonist (Period) that was recently approved for treatment of pulmonary arterial hypertension (PAH). additional ETA selective and nonselective ERAs. Its once daily dosing and lower occurrence of serum aminotransferase elevation present potential advantages over additional ERAs, but additional encounter with this agent is required to grasp its long-term effectiveness … [Read more…]